5 minutes with Graham Clark, CEO, Phastar 

Education or promotion: What wins with HCPs?

Hidden heroes of healthcare: Reaching NPs and PAs

Pharma’s trillion-dollar opportunity: Investing in women’s health

Engaging the medical mind: Does interactivity improve recall?

Hook, line and sinker: Catching the attention of HCPs

Building a high performance customer experience model

Cracking compliance in the US: Key points for pharma to remember

Meeting the growing demand for medical education quizzes

 Designing an excellent customer experience journey

Reaching healthcare professionals with the latest advances

Does pharma have the power to turn back time?

Get ready for Gen Z doctors

Pharma in Ireland

The curious paradox in cardiovascular disease

Should sales be a ‘dirty’ word in medical affairs?

Going for gold in gynaecological cancers

Raising women’s health up the agenda

Unlocking pharma’s creative juices

Pharma in the US

Pharma in the UK

Upgrading the personal touch in CX

Conquering generational differences in HCP marketing

Tipping the scales of KOL success

The brains behind neurological breakthroughs

Challenging the postcode health lottery

Mitigating the rare disease RWD deficit

Is the pharma rep at death’s door?

Pharma in Japan

Following in the footsteps of tech giants

Artificially intelligent drug discovery

Going the extra mile for women’s health

Pharma’s next move in the online jungle

Pharma in India

Pharma in Brazil

Achieving first-time launch success

The physics of pharmacovigilance

Time to turn to TikTok?

Getting into gamification

Behind the hype of ChatGPT

The changing rhythm of digital therapeutics

Pursuing a pathway of preventative medicine

The uphill recruitment battle

Ripples of change in R&D

The future of pharmaceutical sales

NIHR funds £1.5m in innovative digital health projects

ABPI calls for NICE cost-effectiveness threshold review

FTSE 100 hits new high as UK pharma stocks surge

Sanofi commits $625m to Sanofi Ventures

Roche acquires US biotech 89bio for $3.5bn

ABPI report highlights decline in UK pharma investment

Newcastle University wins £22m UK’s NIHR health tech award

UK government establishes RNA Biofoundry

Novo Nordisk taps Replicate’s srRNA platform for obesity

Spotlight: August 2025

AbbVie expands pipeline with psychedelic therapy

Novartis to tackle rare disease diagnosis with AI

New evidence links beta-HPV to skin cancer

FDA and NICE: two leaders step down in same week

Spotlight: July 2025

BMS appoints new EVP, CMO and Head of Development

Daiichi Sankyo’s Laura McMullin appointed ABPI Vice President

New report calls for faster R&D for rare diseases

Spotlight: June 2025

Bayer’s Stefan Oelrich elected as new EFPIA President

US withdraws funding from Gavi, the Vaccine Alliance

FDA investigates trials sending US cells to foreign labs

UK to raise branded drug repayment rate to over 30%

Social media key to Gen Z pharma hires, says ABPI

Sanofi to acquire Blueprint in $9.1bn deal

King’s Fund sheds light on access to medicine in UK

BioNTech commits £1bn to UK in landmark life sciences investment

Trump’s drug pricing order hits pharma stocks

Spotlight: April 2025

Lilly partners with Alchemab for ALS candidate

US unveils new universal vaccine platform

Novartis acquires Regulus Therapeutics and potential first-in-class therapeutic

Ireland launches landmark childhood cancer genomics study

UK enacts new clinical trial regulations

UK government unveils Health Data Research Service

New study shines light on dementia in the workplace

Galen’s Dr Dennise Broderick on why kindness isn’t a weakness in business

Boehringer’s Christoph von der Goltz on setbacks and success in R&D

DeepHealth’s Naiara Martínez Cabrera on AI’s role in radiology

J&J’s Martin Price on World Cancer Day 2025 – Part 2

J&J’s Martin Price on World Cancer Day 2025 – Part 1